Transmyocardial and percutaneous myocardial revascularization: Current and future role in the treatment of coronary artery disease

Birgit Kantor, Charles J. McKenna, James A. Caccitolo, Katsumi Miyauchi, Guy S. Reeder, Charles J. Mullany, Hartzell V. Schaff, David R. Holmes, Robert S. Schwartz

Research output: Contribution to journalArticle

19 Scopus citations


Transmyocardial revascularization (TMR) is a new treatment modality under evaluation in patients with severely symptomatic, diffuse coronary artery disease, in whom the potential for medical or interventional management has been exhausted. Preliminary clinical trials show improved ischemic symptoms within the first 3 months in about 70% of TMR-treated patients. The original proposed mechanism of surgical or catheter-based TMR (percutaneous myocardial revascularization [PMR]) was that channels mediate direct blood flow between the left ventricular cavity and ischemic myocardium. However, several alternative explanations for the clinical success of TMR have recently been suggested, including improved perfusion by angiogenesis, an anesthetic effect by nerve destruction, and a potential placebo effect. This article reviews the clinical role of TMR/PMR, its possible pathophysiologic mechanisms, and its controversies. It provides an overview of the actual scientific and clinical status of TMR and details future directions.

Original languageEnglish (US)
Pages (from-to)585-592
Number of pages8
JournalMayo Clinic proceedings
Issue number6
StatePublished - Jan 1 1999


ASJC Scopus subject areas

  • Medicine(all)

Cite this